Clinical Trials for Non-Small Cell Lung Cancer

MC220806: Phase I Study Evaluating the Efficacy of CSF1R and TAM Receptor or Inhibition in Hematologic Malignancies With Q702, a Small Molecular Inhibitor

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with relapsed/refractory histiocytic neoplasms (including ECD, LCH, histiocytic sarcoma, Rosai-Dorfman) lacking actionable BRAF/MAP2K alterations or post–BRAF/MEK, plus high‑risk MDS/CMML/MF post‑standard therapy, and multiple relapsed/refractory lymphomas/CLL after ≥2 prior lines, receive oral Q702 (adrixetinib), a TAM kinase (AXL/MERTK) and CSF1R inhibitor given week-on/week-off. The trial assesses safety, RP2D, and preliminary efficacy across disease-specific cohorts.

ClinicalTrials.gov ID: NCT06712810

Phase 2 Study of Zelenectide Pevedotin in Participants With Previously-Treated NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

TrialFetch AI summary: Adults with advanced/metastatic NSCLC harboring centrally confirmed NECTIN4 gene amplification (non-squamous and squamous cohorts), previously treated with up to 3 prior lines (including prior platinum/IO or appropriate targeted therapy for actionable drivers), receive zelenectide pevedotin (BT8009) monotherapy. BT8009 is a Nectin-4–targeted Bicycle Toxin Conjugate delivering MMAE; key exclusions include prior MMAE, active/untreated CNS mets, significant ocular disease, and active ILD/pneumonitis.

ClinicalTrials.gov ID: NCT06933329

A Phase 1/2 Study Evaluating the Safety and Efficacy of Amivantamab and Olomorasib Combination Therapy in Metastatic Non-small Cell Lung Cancer

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with metastatic NSCLC harboring KRAS G12C (ECOG 0–1) who have progressed on or are intolerant to platinum chemotherapy and PD-(L)1 therapy (no prior KRAS inhibitor; no other actionable driver alterations; stable/asymptomatic treated brain metastases allowed). Patients receive IV amivantamab (EGFR/MET bispecific antibody) in combination with oral olomorasib/LY3537982 (selective KRAS G12C inhibitor binding the GDP-bound mutant) until progression or unacceptable toxicity.

ClinicalTrials.gov ID: NCT07227025

A Phase 2 Study of DRP-104, a Glutamine Antagonist, in Patients With NFE2L2/KEAP1-altered Non-Small Cell Lung Cancer

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

TrialFetch AI summary: Enrolling adults with advanced/metastatic or unresectable NSCLC harboring NFE2L2 or KEAP1 alterations who have RECIST-measurable disease and have progressed after prior platinum-based chemotherapy and anti–PD-1/PD-L1 therapy (ECOG 0–1; stable treated brain metastases allowed). Patients receive single-agent DRP-104 (sirpiglenastat) subcutaneously twice weekly in continuous 21-day cycles; DRP-104 is a tumor-targeted prodrug of DON, a broad glutamine antagonist that irreversibly inhibits multiple glutamine-utilizing enzymes.

ClinicalTrials.gov ID: NCT07249372

A Phase I/IIa, Open-label, Dose-escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Preliminary Anti-tumor Activity of H002 in Patients With Active EGFR Mutation Locally Advanced or Metastatic NSCLC

TrialFetch AI summary: This trial involves adults with unresectable locally advanced or metastatic NSCLC harboring active EGFR mutations, including C797S, who have progressed on osimertinib or another third-generation EGFR-TKI, receiving the investigational fourth-generation EGFR tyrosine kinase inhibitor H002 to assess its safety and preliminary anti-tumor activity.

ClinicalTrials.gov ID: NCT05519293

A Phase 1, Open-Label Study of ABSK112 to Assess Safety, Tolerability, and Pharmacokinetics in Patients With Non-Small Cell Lung Cancer

TrialFetch AI summary: This trial evaluates ABSK112, a small molecule targeting EGFR exon 20 insertion mutations, in patients with locally advanced or metastatic non-small cell lung cancer characterized by these mutations, focusing on its safety, tolerability, and pharmacokinetics. The study involves dose escalation and an expansion cohort, enrolling adults with measurable disease and a life expectancy of at least three months.

ClinicalTrials.gov ID: NCT06225804

LOcally ABLatIve ThErapy for OligopRogressive Lung And Thoracic MalignanciEs (OBLITERATE)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: This trial targets adult patients with non-small cell and small cell lung cancers experiencing oligo-progression while on stable systemic therapy, assessing the addition of locally ablative therapies like stereotactic ablative radiotherapy (SABR) and interventional radiology ablation for up to five or fewer metastatic lesions.

ClinicalTrials.gov ID: NCT06103682

SiCARIO (Split Course Adaptive Radioimmunotherapy) for the Treatment of Oligometastatic Non-Small Cell Lung Cancer (NSCLC) Using Biologically-Adaptive Radiotherapy - A Phase I/II Study

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: This trial involves adults with stage IVA/IVB or locally advanced NSCLC unsuitable for standard chemoradiation, using split-course adaptive radiation therapy combined with immunotherapy agents like pembrolizumab and ipilimumab, which enhance immune targeting of cancer cells, with or without standard chemotherapy like carboplatin.

ClinicalTrials.gov ID: NCT05501665

Phase I Study of Gilteritinib for ALK Positive Non-Small Cell Lung Cancer

TrialFetch AI summary: The trial involves previously treated adult patients with stage IV ALK positive non-small cell lung cancer, evaluating the safety and optimal dosing of gilteritinib, an investigational drug that targets the FLT3 receptor tyrosine kinase. Patients must have progressed on first and second-generation ALK TKIs and may have had chemotherapy or other antineoplastic treatments.

ClinicalTrials.gov ID: NCT06225427

Molecularly Targeted Radionuclide Therapy Via the Integrin Alphavbeta6

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: This trial investigates the safety and efficacy of [68Ga]Ga DOTA-5G for imaging and [177Lu]Lu DOTA-ABM-5G for treatment, targeting the integrin αvβ6, in up to 40 patients with metastatic non-small cell lung cancer who have progressed after previous treatments.

ClinicalTrials.gov ID: NCT06228482